Richard Law
Stock Analyst at Goldman Sachs
(1.67)
# 3,388
Out of 5,005 analysts
67
Total ratings
25%
Success rate
8.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Maintains: Neutral | $35 → $40 | $40.86 | -2.10% | 1 | Sep 26, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $32 → $52 | $38.06 | +36.63% | 7 | Sep 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $27 → $30 | $21.65 | +38.57% | 4 | Aug 7, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Buy | $74 → $82 | $8.43 | +872.72% | 4 | Aug 6, 2025 | |
| ARQT Arcutis Biotherapeutics | Initiates: Neutral | $18 | $19.92 | -9.64% | 1 | Jul 25, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Buy | $20 → $18 | $11.10 | +62.16% | 5 | May 14, 2025 | |
| SLN Silence Therapeutics | Maintains: Sell | $4 → $3 | $5.00 | -40.00% | 3 | May 9, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Neutral | $15 → $13 | $3.15 | +312.70% | 3 | May 9, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Neutral | $36 → $31 | $26.41 | +17.38% | 3 | May 9, 2025 | |
| VKTX Viking Therapeutics | Initiates: Neutral | $30 | $29.72 | +0.94% | 1 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $73 | $94.29 | -22.58% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $11 | $7.74 | +42.12% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $47 | $25.75 | +82.52% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $63 | $67.74 | -7.00% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $57.90 | -36.10% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $19.96 | +280.76% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $3.92 | +257.14% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $9.61 | +534.76% | 4 | May 8, 2023 |
Crinetics Pharmaceuticals
Sep 26, 2025
Maintains: Neutral
Price Target: $35 → $40
Current: $40.86
Upside: -2.10%
Mineralys Therapeutics
Sep 9, 2025
Maintains: Buy
Price Target: $32 → $52
Current: $38.06
Upside: +36.63%
Viridian Therapeutics
Aug 7, 2025
Maintains: Buy
Price Target: $27 → $30
Current: $21.65
Upside: +38.57%
MoonLake Immunotherapeutics
Aug 6, 2025
Maintains: Buy
Price Target: $74 → $82
Current: $8.43
Upside: +872.72%
Arcutis Biotherapeutics
Jul 25, 2025
Initiates: Neutral
Price Target: $18
Current: $19.92
Upside: -9.64%
Olema Pharmaceuticals
May 14, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $11.10
Upside: +62.16%
Silence Therapeutics
May 9, 2025
Maintains: Sell
Price Target: $4 → $3
Current: $5.00
Upside: -40.00%
Rocket Pharmaceuticals
May 9, 2025
Maintains: Neutral
Price Target: $15 → $13
Current: $3.15
Upside: +312.70%
Celldex Therapeutics
May 9, 2025
Maintains: Neutral
Price Target: $36 → $31
Current: $26.41
Upside: +17.38%
Viking Therapeutics
Apr 8, 2025
Initiates: Neutral
Price Target: $30
Current: $29.72
Upside: +0.94%
Nov 21, 2024
Initiates: Buy
Price Target: $73
Current: $94.29
Upside: -22.58%
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $7.74
Upside: +42.12%
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $25.75
Upside: +82.52%
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $67.74
Upside: -7.00%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $57.90
Upside: -36.10%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $19.96
Upside: +280.76%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $3.92
Upside: +257.14%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $9.61
Upside: +534.76%